Ok Bozkaya İkbal, Yaralı Neşe, Işık Pamir, Ünsal Saç Rukiye, Tavil Betül, Tunç Bahattin
Ankara Children's Hematology Oncology Hospital, Clinic of Pediatric Hematology, Ankara, Turkey Phone: +90 312 396 99 70 E-mail:
Turk J Haematol. 2015 Jun;32(2):172-4. doi: 10.4274/tjh.2013.0191.
Congenital amegakaryocytic thrombocytopenia (CAMT) generally begins at birth with severe thrombocytopenia and progresses to pancytopenia. It is caused by mutations in the thrombopoietin receptor gene, the myeloproliferative leukemia virus oncogene (c-MPL). The association between CAMT and c-MPL mutation type has been reported in the literature. Patients with CAMT have been categorized according to their clinical symptoms caused by different mutations. Missense mutations of c-MPL have been classified as type II and these patients have delayed onset of bone marrow failure compared to type I patients. Here we present a girl with severe clinical course of CAMT II having a missense mutation in exon 4 of the c-MPL gene who was admitted to our hospital with intracranial hemorrhage during the newborn period.
先天性无巨核细胞血小板减少症(CAMT)通常在出生时就开始出现严重血小板减少,并进展为全血细胞减少。它是由血小板生成素受体基因、骨髓增殖性白血病病毒癌基因(c-MPL)的突变引起的。文献中已报道了CAMT与c-MPL突变类型之间的关联。CAMT患者已根据由不同突变引起的临床症状进行了分类。c-MPL的错义突变被归类为II型,与I型患者相比,这些患者的骨髓衰竭发病较晚。在此,我们报告一名患有严重CAMT II临床病程的女孩,其c-MPL基因第4外显子存在错义突变,在新生儿期因颅内出血入住我院。